Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00736879 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 497
- Enrollment target
- 20
- Study locations
NCT00736879 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by AstraZeneca. The registered enrollment target is 497 participants, below the 2,744-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00736879, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 497 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Study Locations (20)
California
- Valley Research - Fresno
- Marina Raikhel, Md, Faafp - Lomita
- Richard S. Cherlin, Md - Los Gatos
- Orange County Research Center - Tustin
Arizona
- Dedicated Clinical Research - Litchfield Park
- 43rd Medical Associates, P.C. - Phoenix
- Clinical Research Advantage, Inc. - Tempe
Florida
- Central Florida Clinical Trials, Inc. - Altamonte Springs
- Westside Center For Clinical Research - Jacksonville
- Panhandle Family Care Associates - Marianna
New York
- Internist Associates Of Central New York - Syracuse
- Southgate Medical Group - West Seneca
Colorado
- Family Physicians Of Greeley - Greeley
Connecticut
- Coastal Connecticut Research, Llc - New London
Georgia
- Endocrine Research Solutions, Inc. - Roswell
Mississippi
- Belzoni Clinical Research - Belzoni
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2008-09-22 |
| Est. Completion | 2009-12-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00736879
The ClinicalTrials.gov registry entry for NCT00736879 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 497 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,744-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (82% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00736879 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00736879 about?
NCT00736879 is a clinical study titled "Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes". The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied
What is the current status of trial NCT00736879?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 497 participants. The study started on 2008-09-22. Estimated completion is 2009-12-29.
What conditions does trial NCT00736879 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00736879?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00736879?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00736879 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.